Abstract
Unique among ion channels, TRPM6 and TRPM7 garnered much interest upon their discovery as the first ion channels to possess their own kinase domain. Soon after their identification, the two proteins were quickly linked to the regulation of magnesium homeostasis. However, study of their physiological functions in mouse and zebrafish have revealed expanding roles for these channel-kinases that include skeletogenesis and melanopore formation, thymopoiesis, cell adhesion, and neural fold closure during early development. In addition, mutations in the TRPM6 gene constitute the underlying genetic defect in hypomagnesemia with secondary hypocalcemia, a rare autosomal-recessive disease characterized by low serum magnesium accompanied by hypocalcemia. Depletion of TRPM7 expression in brain, on the other hand, proved successful in mitigating much of the cellular devastation that accompanies oxygen-glucose deprivation during ischemia. The aim of this review is to summarize the data emerging from molecular genetic, biochemical, electrophysiological, and pharmacological studies of these unique channel-kinases.
Keywords: TRPM6, channel, kinase, calcium, magnesium, TRPM7, Mul-TRP-PLIK-Cation, magnesium homeostasis, skeletogenesis, melanopore formation, thymopoiesis, cell adhesion, hypomagnesemia, hypocalcemia, melanoma kinase, protein kinases, TRP-PLIK, LTRPC7, CHAK1, transient receptor potential, kidney kinase, COOH-terminal tails, Dictyostelium myosin II heavy chain kinases, elongation factor 2 kinase, phosphorylation, alpha-kinases, PKA, autophosphorylation, dimerization sequence, Xenopus oocytes, CHO-K1 cells, TRPM6 cDNA, non-selective channel blocker 2-APB, GXGXXG, CHO-K1, pyrimidine-based nucleoside triphosphates, TRPM7--kinase, Gly1799, Demeuse's measurements, phospholipase C-1 (PLC1), cAMP, 17--estradiol, DT40-KO, KMG104AM, small interfering RNA, TGF-1,, bradykinin-stimulated Ca2+, myosin IIA
Current Pharmaceutical Biotechnology
Title: TRPM6 and TRPM7: A Mul-TRP-PLIK-Cation of Channel Functions
Volume: 12 Issue: 1
Author(s): Loren W. Runnels
Affiliation:
Keywords: TRPM6, channel, kinase, calcium, magnesium, TRPM7, Mul-TRP-PLIK-Cation, magnesium homeostasis, skeletogenesis, melanopore formation, thymopoiesis, cell adhesion, hypomagnesemia, hypocalcemia, melanoma kinase, protein kinases, TRP-PLIK, LTRPC7, CHAK1, transient receptor potential, kidney kinase, COOH-terminal tails, Dictyostelium myosin II heavy chain kinases, elongation factor 2 kinase, phosphorylation, alpha-kinases, PKA, autophosphorylation, dimerization sequence, Xenopus oocytes, CHO-K1 cells, TRPM6 cDNA, non-selective channel blocker 2-APB, GXGXXG, CHO-K1, pyrimidine-based nucleoside triphosphates, TRPM7--kinase, Gly1799, Demeuse's measurements, phospholipase C-1 (PLC1), cAMP, 17--estradiol, DT40-KO, KMG104AM, small interfering RNA, TGF-1,, bradykinin-stimulated Ca2+, myosin IIA
Abstract: Unique among ion channels, TRPM6 and TRPM7 garnered much interest upon their discovery as the first ion channels to possess their own kinase domain. Soon after their identification, the two proteins were quickly linked to the regulation of magnesium homeostasis. However, study of their physiological functions in mouse and zebrafish have revealed expanding roles for these channel-kinases that include skeletogenesis and melanopore formation, thymopoiesis, cell adhesion, and neural fold closure during early development. In addition, mutations in the TRPM6 gene constitute the underlying genetic defect in hypomagnesemia with secondary hypocalcemia, a rare autosomal-recessive disease characterized by low serum magnesium accompanied by hypocalcemia. Depletion of TRPM7 expression in brain, on the other hand, proved successful in mitigating much of the cellular devastation that accompanies oxygen-glucose deprivation during ischemia. The aim of this review is to summarize the data emerging from molecular genetic, biochemical, electrophysiological, and pharmacological studies of these unique channel-kinases.
Export Options
About this article
Cite this article as:
W. Runnels Loren, TRPM6 and TRPM7: A Mul-TRP-PLIK-Cation of Channel Functions, Current Pharmaceutical Biotechnology 2011; 12 (1) . https://dx.doi.org/10.2174/138920111793937880
DOI https://dx.doi.org/10.2174/138920111793937880 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry Non-IgE Mediated Food Allergy – Update of Recent Progress in Mucosal Immunity
Inflammation & Allergy - Drug Targets (Discontinued) P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design
Current Topics in Medicinal Chemistry The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Current Signal Transduction Therapy Metabolic Activation of Herbal and Dietary Constituents and Its Clinical and Toxicological Implications: An Update
Current Drug Metabolism 25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Design and Development of Molecular Imaging Probes
Current Topics in Medicinal Chemistry The Crosstalk between Gut Microbiota, Intestinal Immunological Niche and Visceral Adipose Tissue as a New Model for the Pathogenesis of Metabolic and Inflammatory Diseases: The Paradigm of Type 2 Diabetes Mellitus
Current Medicinal Chemistry Pharmacological Effects and Chemical Constituents of Bupleurum
Mini-Reviews in Medicinal Chemistry Phospho-eIF4E: A New Target for Acute Myeloid Leukemia
Current Protein & Peptide Science Cyclodextrin-based Polymeric Nanoparticles as Efficient Carriers for Anticancer Drugs
Current Pharmaceutical Biotechnology Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design Fatty Acid Synthase: A Target for the Reversal of Liver Steatosis
Current Enzyme Inhibition Targeting the SUMO E2 Conjugating Enzyme Ubc9 Interaction for Anti-Cancer Drug Design
Anti-Cancer Agents in Medicinal Chemistry Antioxidant Therapeutic Approaches Toward Amelioration of the Pulmonary Pathophysiological Damaging Effects of Ionizing Irradiation
Current Respiratory Medicine Reviews Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets